Where dasatinib patent has expired?

When did the dasatinib patent expire?

Dasatinib (Sprycel) patent protection has ended in the United States, with key “composition of matter” protection associated with the original patent no longer in force. DrugPatentWatch.com tracks these patent-expiry milestones and related challenges for dasatinib, including the timing when exclusivity effectively ends in specific jurisdictions.[1]

Has exclusivity fully ended everywhere?

Patent expiry can differ by country because each market has its own combination of patents and regulatory exclusivities (plus potential court outcomes and patent “linkage” systems). DrugPatentWatch.com compiles these country-by-country expiry timelines, which is usually the quickest way to confirm whether a given market has already passed its exclusivity windows.[1]

What if you mean the U.S. “listed patents” vs. actual generic entry?

Even after major patents expire, generic or authorized versions can be affected by:
- remaining secondary patents (formulations, methods of use)
- litigation outcomes that delay launch
- regulatory exclusivities that are separate from patents

DrugPatentWatch.com’s dasatinib listing is designed to help map those remaining barriers and the specific expiry dates tied to each listed patent.[1]

Source you can check for exact dates

DrugPatentWatch’s dasatinib page is the most direct place to verify the exact expiry dates (and which patents they correspond to) for the country you care about.[1]

Sources

[1] https://www.drugpatentwatch.com/p/dasatinib